Valvular & structural heart disease
Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation
Study context
- Population
- Patients undergoing transcatheter aortic valve implantation (TAVI) without oral anticoagulation (OAC) indication, at high ischaemic risk (concomitant CAD, DM or peripheral vascular disease)planned enrolment
- Participants
- 1,206 patients
- Planned comparison
- Low-dose ticagrelor vs aspirin as single antiplatelet therapy after TAVI
- Primary endpoint
- Net adverse clinical event (NACE) (all-cause mortality, cerebrovascular events, MI, progressive angina leading to emergency evaluation, rehospitalization or new coronary angiogram, clinical valve thrombosis, acute limb ischemia leading to hospitalization, type 2, 3 or 5 bleeding)
- Follow-up
- 1 year after TAVI
Methodological detailsprospective, multicentre, open-label, phase III, 1:1 randomisation
- Prospective
- Multicentre
- Open-label
- Phase III
- 1:1 randomisation
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of REAC-TAVI 2: Single antiplatelet treatment with ticagrelor vs aspirin after transcatheter aortic valve implantation. Am Heart J. Published 1 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →